Enanta Pharmaceuticals (ENTA) Income towards Parent Company: 2012-2025
Historic Income towards Parent Company for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$18.6 million.
- Enanta Pharmaceuticals' Income towards Parent Company rose 35.08% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.8 million, marking a year-over-year increase of 29.41%. This contributed to the annual value of -$81.8 million for FY2025, which is 29.41% up from last year.
- According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Income towards Parent Company is -$18.6 million, which was down 1.82% from -$18.3 million recorded in Q2 2025.
- In the past 5 years, Enanta Pharmaceuticals' Income towards Parent Company ranged from a high of -$18.3 million in Q2 2025 and a low of -$39.1 million during Q2 2023.
- In the last 3 years, Enanta Pharmaceuticals' Income towards Parent Company had a median value of -$28.1 million in 2023 and averaged -$27.5 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 503.91% in 2021, then spiked by 42.00% in 2024.
- Enanta Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$30.1 million in 2021, then rose by 3.75% to -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then skyrocketed by 35.08% to -$18.6 million in 2025.
- Its Income towards Parent Company stands at -$18.6 million for Q3 2025, versus -$18.3 million for Q2 2025 and -$22.6 million for Q1 2025.